Q32 Bio (QTTB) Competitors $2.07 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.06 -0.01 (-0.48%) As of 10/3/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. IFRX, PLRX, VXRT, CNTB, ASRT, EQ, CNTX, OVID, QNCX, and SLGLShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include InflaRx (IFRX), Pliant Therapeutics (PLRX), Vaxart (VXRT), Connect Biopharma (CNTB), Assertio (ASRT), Equillium (EQ), Context Therapeutics (CNTX), Ovid Therapeutics (OVID), Quince Therapeutics (QNCX), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors InflaRx Pliant Therapeutics Vaxart Connect Biopharma Assertio Equillium Context Therapeutics Ovid Therapeutics Quince Therapeutics Sol-Gel Technologies Q32 Bio (NASDAQ:QTTB) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has more risk & volatility, QTTB or IFRX? Q32 Bio has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Is QTTB or IFRX more profitable? InflaRx's return on equity of -71.76% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -2,709.70% -61.16% InflaRx N/A -71.76%-57.68% Which has higher valuation & earnings, QTTB or IFRX? Q32 Bio has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M21.77-$47.73M-$4.30-0.48InflaRx$162.83K651.43-$49.85M-$0.80-1.98 Do analysts prefer QTTB or IFRX? Q32 Bio presently has a consensus price target of $12.17, indicating a potential upside of 487.76%. InflaRx has a consensus price target of $6.20, indicating a potential upside of 292.41%. Given Q32 Bio's higher probable upside, research analysts plainly believe Q32 Bio is more favorable than InflaRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11InflaRx 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals and insiders believe in QTTB or IFRX? 31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 40.0% of Q32 Bio shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor QTTB or IFRX? In the previous week, InflaRx had 1 more articles in the media than Q32 Bio. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.00 beat InflaRx's score of -1.00 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative SummaryInflaRx beats Q32 Bio on 9 of the 15 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.25M$3.33B$6.09B$10.56BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-0.4822.1478.0526.71Price / Sales21.77416.32577.62178.63Price / CashN/A47.2037.7961.25Price / Book4.409.9312.556.56Net Income-$47.73M-$52.80M$3.31B$277.70M7 Day Performance9.52%5.22%4.28%2.41%1 Month Performance24.70%13.01%7.85%9.30%1 Year Performance-95.37%25.18%71.37%31.22% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.5414 of 5 stars$2.07flat$12.17+487.8%-95.2%$25.25M$1.16M-0.4839News CoverageAnalyst UpgradeIFRXInflaRx2.0604 of 5 stars$1.35+0.7%$6.20+359.3%+1.3%$89.96M$180K-1.6960Positive NewsShort Interest ↑PLRXPliant Therapeutics4.1378 of 5 stars$1.50+4.9%$8.19+445.8%-86.3%$87.79M$1.58M-0.4490Positive NewsVXRTVaxart2.4508 of 5 stars$0.38-1.0%$2.00+422.1%-55.9%$87.71M$47.40M-1.42120CNTBConnect Biopharma3.8351 of 5 stars$1.58+0.6%$7.00+343.0%+1.7%$87.48M$26.03M0.00110Short Interest ↓ASRTAssertio1.9819 of 5 stars$0.93+2.5%$2.38+156.1%-16.6%$87.03M$124.96M-2.0620EQEquillium0.571 of 5 stars$1.45-0.7%$1.00-31.0%+58.2%$86.88M$41.10M-2.5940CNTXContext Therapeutics3.202 of 5 stars$0.99+2.4%$5.20+424.4%-44.4%$86.85MN/A-2.757News CoverageAnalyst ForecastGap UpOVIDOvid Therapeutics4.611 of 5 stars$1.29+6.6%$3.10+140.3%+62.8%$86.04M$570K-2.4360Trending NewsOptions VolumeGap UpQNCXQuince Therapeutics3.2501 of 5 stars$1.62+1.3%$8.14+402.6%+120.0%$85.94MN/A-1.4960News CoverageSLGLSol-Gel Technologies0.3348 of 5 stars$28.01-8.2%N/A+434.5%$84.97M$11.54M-22.7750Gap Up Related Companies and Tools Related Companies InflaRx Competitors Pliant Therapeutics Competitors Vaxart Competitors Connect Biopharma Competitors Assertio Competitors Equillium Competitors Context Therapeutics Competitors Ovid Therapeutics Competitors Quince Therapeutics Competitors Sol-Gel Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
